ArticleActa neurologica Belgica2026
Dysregulation of ferroptosis-related plasma biomarkers in treatment-free patients with relapsing-remitting multiple sclerosis in clinical remission: a case-control study.
Article in Acta neurologica Belgica, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundFerroptosis, an iron-dependent form of programmed cell death characterized by lipid peroxidation, has emerged as a key mechanism associated with neuroinflammation. This process is particularly relevant in relapsing-remitting multiple sclerosis (RRMS), where neuroinflammatory pathways contribute significantly to disease pathology.
methodsThis study included 38 patients with RRMS and 38 healthy controls. Plasma levels of key ferroptosis-related biomarkers, including malondialdehyde (MDA), glutathione (GSH), and glutathione peroxidase 4 (GPX4), as well as iron and ferritin, were analyzed.
resultsThe analysis demonstrated significantly elevated levels of MDA, iron, and ferritin in the RRMS group compared to the control group with p-values of 0.004, 0.042, and 0.038, respectively. Conversely, GSH and GPX4 levels were significantly reduced in the RRMS group with p-values of 0.028, and 0.014, respectively. A significant correlation was observed between MDA and iron levels in the control group (r = 0.346, p = 0.045).
conclusionThe significant differences in plasma levels of ferroptosis-related biomarkers between RRMS patients and healthy controls suggest a potential role for ferroptosis in the pathogenesis of multiple sclerosis.
Indexed as
Identifiers
42545622What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.